Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer accounting for approximately 85% of all lung cancers, and is often associated with a poor treatment outcome and high mortality. Treatment options for NSCLC include surgery, radiofrequency ablation, radiation therapy, chemotherapy, and immunotherapy. The presence of certain mutations in NSCLC enables treatment with drugs targeting the mutations.
We assisted our client in generating evidence surrounding efficacy and safety of available treatment options that target advanced NSCLC variants which carry mutations in the BRAF gene, including conventional non-targeted therapy as well as targeted therapy, from the Canadian perspective, by performing data abstraction and curation through screening of around 1100 papers through 2 levels of screening, and identified 11 eligible papers from which we extracted relevant data.
For a different project, we assisted our client in compiling data about clinical effectiveness of a monoclonal antibody for the immunotherapy (both mono and in combination) of advanced NSCLC by screening around 1950 papers over 2 levels of screening, and subsequently extracted data from 194 studies. We also assisted in updating this SLR in the next year with by performing data abstraction from over 2000 new papers and extracting data from 92 studies.
In another project, we assisted our client in evaluating the efficacy and safety of a monoclonal antibody in combination with radiotherapy in patients with advanced NSCLC by extracting data from around 100 studies.
We helped our client in collating evidence on the epidemiology, humanistic and economic burden, treatment patterns, and clinical outcomes among patients with advanced stages of both NSCLC and SCLC without any specific mutations of interest, who had received at least one session of check-point inhibitor (CPI) therapy or platinum-based therapy as a part of another project: we identified relevant studies by performing data abstraction from over 3800 records over 2 levels of screening. Therapy area: Oncology